Related Experiment Video

Updated: Aug 17, 2026

Tracking Fibrinolysis of Chandler Loop-Formed Whole Blood Clots Under Shear Flow in An In-Vitro Thrombolysis Model
06:16

Tracking Fibrinolysis of Chandler Loop-Formed Whole Blood Clots Under Shear Flow in An In-Vitro Thrombolysis Model

Published on: April 19, 2024

Direct thrombin inhibitors: current status and future prospects

K Menear1

  • 1Novartis Horsham Research Centre, Wimblehurst Road, Horsham, West Sussex, RH12 4AB, UK. keith.menear@pharma.novartis.com

Expert Opinion on Investigational Drugs
|July 5, 2005
PubMed

Insights

Direct thrombin inhibitors offer a new approach to treating thrombosis, a major cause of heart disease. Clinical evidence shows promise for these agents, with new oral options in development.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Thrombin is a key enzyme in blood coagulation and thrombosis, a significant cause of coronary syndromes, mortality, and morbidity.
  • Current antithrombotic therapies include aspirin, heparin, and warfarin, but direct thrombin inhibition presents a novel therapeutic strategy.

Purpose of the Study:

  • To review the clinical evidence for direct thrombin inhibitors in modulating thrombosis.
  • To identify key clinical parameters and areas for improvement for newer direct thrombin inhibitor compounds.

Main Methods:

  • Analysis of clinical evidence from trials involving recombinant and synthetic thrombin inhibitors.
  • Evaluation of early clinical development of low molecular weight, orally available thrombin inhibitors.

Main Results:

  • Clinical studies provide insights into the therapeutic potential of direct thrombin inhibitors.
  • Established therapies like aspirin, heparin, and warfarin are being challenged by this new class of drugs.
  • Phase III trials with hirudin-based compounds have raised questions addressed by newer agents.

Conclusions:

  • Direct thrombin inhibitors represent a significant advancement in antithrombotic therapy.
  • Ongoing development of orally available compounds aims to overcome limitations of current treatments.
  • Further research is needed to fully elucidate the clinical benefits and optimal use of these novel agents.

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...